{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T20:32:35Z","timestamp":1778272355871,"version":"3.51.4"},"reference-count":72,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1016\/j.clml.2016.06.006","type":"journal-article","created":{"date-parts":[[2016,6,9]],"date-time":"2016-06-09T22:41:00Z","timestamp":1465512060000},"page":"495-502","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Vaccination in Multiple Myeloma: Review of Current Literature"],"prefix":"10.1016","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7778-9044","authenticated-orcid":false,"given":"Andinet","family":"Alemu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John O.","family":"Richards","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin K.","family":"Oaks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael A.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2016.06.006_bib1","first-page":"1","article-title":"Deaths: leading causes for 2008","volume":"60","author":"Heron","year":"2012","journal-title":"Natl Vital Stat Rep"},{"key":"10.1016\/j.clml.2016.06.006_bib2","first-page":"1","article-title":"Mortality in the United States, 2013","volume":"178","author":"Kochanek","year":"2014","journal-title":"NCHS Data Brief"},{"key":"10.1016\/j.clml.2016.06.006_bib3","doi-asserted-by":"crossref","first-page":"5086","DOI":"10.1016\/j.vaccine.2007.03.046","article-title":"The annual impact of seasonal influenza in the US: measuring disease burden and costs","volume":"25","author":"Molinari","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.clml.2016.06.006_bib4","first-page":"1","article-title":"Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010","volume":"59","author":"Fiore","year":"2010","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.clml.2016.06.006_bib5","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1056\/NEJM197510302931801","article-title":"Impaired synthesis of polyclonal (non-paraprotein) immunoglobulins by circulating lymphocytes from patients with multiple myeloma: role of suppressor cells","volume":"293","author":"Broder","year":"1975","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2016.06.006_bib6","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/BF00915255","article-title":"Humoral immune deficiency in multiple myeloma patients due to compromised B-cell function","volume":"6","author":"Pilarski","year":"1986","journal-title":"J\u00a0Clin Immunol"},{"key":"10.1016\/j.clml.2016.06.006_bib7","doi-asserted-by":"crossref","first-page":"9219","DOI":"10.1200\/JCO.2005.03.2086","article-title":"Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United Kingdom Medical Research Council trials between 1980 and 2002\u2014Medical Research Council Adult Leukaemia Working Party","volume":"23","author":"Augustson","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2016.06.006_bib8","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3324\/haematol.2014.107714","article-title":"Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients","volume":"100","author":"Blimark","year":"2015","journal-title":"Haematolgica"},{"key":"10.1016\/j.clml.2016.06.006_bib9","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1383\/medc.33.3.17.61116","article-title":"Immunization","volume":"33","author":"Bellamy","year":"2005","journal-title":"Medicine"},{"key":"10.1016\/j.clml.2016.06.006_bib10","doi-asserted-by":"crossref","first-page":"73","DOI":"10.4103\/0974-777X.77299","article-title":"Fundamentals of vaccine immunology","volume":"3","author":"Clem","year":"2011","journal-title":"J\u00a0Glob Infect Dis"},{"key":"10.1016\/j.clml.2016.06.006_bib11","series-title":"Kuby Immunology","author":"Kindt","year":"2007"},{"key":"10.1016\/j.clml.2016.06.006_bib12","series-title":"Vaccines","first-page":"17","article-title":"Vaccine immunology","author":"Siegrist","year":"2008"},{"key":"10.1016\/j.clml.2016.06.006_bib13","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1086\/313947","article-title":"Clinical relevance of age-related immune dysfunction","volume":"31","author":"Castle","year":"2000","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clml.2016.06.006_bib14","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3324\/haematol.2012.067272","article-title":"Analysis of the immune system of multiple myeloma patients achieving long-term disease control by multidimensional flow cytometry","volume":"98","author":"Pessoa de Magalh\u00e3es","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2016.06.006_bib15","doi-asserted-by":"crossref","first-page":"2962","DOI":"10.1182\/blood-2007-10-078022","article-title":"Multiple myeloma","volume":"111","author":"Kyle","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2016.06.006_bib16","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1007\/s00018-016-2135-z","article-title":"Immune responses in multiple myeloma: role of the natural immune surveillance and potential of immunotherapies","volume":"73","author":"Guillerey","year":"2016","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.clml.2016.06.006_bib17","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.15252\/emmm.201505301","article-title":"Lost in translation: pluripotent stem cell-derived hematopoiesis","volume":"7","author":"Ackermann","year":"2015","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.clml.2016.06.006_bib18","doi-asserted-by":"crossref","first-page":"C987","DOI":"10.1152\/ajpcell.00406.2006","article-title":"Stroma-derived factor (SDF-1\/CXCL12) and human tumor pathogenesis","volume":"292","author":"Kryczek","year":"2007","journal-title":"Am J Physiol Cell Physiol"},{"key":"10.1016\/j.clml.2016.06.006_bib19","doi-asserted-by":"crossref","first-page":"196063","DOI":"10.1155\/2012\/196063","article-title":"Targeting multiple-myeloma-induced immune dysfunction to improve immunotherapy outcomes","volume":"2012","author":"Rutella","year":"2012","journal-title":"Clin Dev Immunol"},{"key":"10.1016\/j.clml.2016.06.006_bib20","doi-asserted-by":"crossref","first-page":"4745","DOI":"10.4049\/jimmunol.175.7.4745","article-title":"A\u00a0novel role of hepatocyte growth factor as an immune regulator through suppressing dendritic cell function","volume":"175","author":"Okunishi","year":"2005","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.clml.2016.06.006_bib21","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1186\/1479-5876-10-247","article-title":"Indoleamine 2,3-dioxygenase 1 (IDO1) activity correlates with immune system abnormalities in multiple myeloma","volume":"10","author":"Bonanno","year":"2012","journal-title":"J\u00a0Transl Med"},{"key":"10.1016\/j.clml.2016.06.006_bib22","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1385\/IR:23:2-3:263","article-title":"VEGF as a mediator of tumor-associated immunodeficiency","volume":"23","author":"Ohm","year":"2001","journal-title":"Immunol Res"},{"key":"10.1016\/j.clml.2016.06.006_bib23","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/nri2506","article-title":"Myeloid-derived suppressor cells as regulators of the immune system","volume":"9","author":"Gabrilovich","year":"2009","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.clml.2016.06.006_bib24","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4065\/78.1.21","article-title":"Review of 1027 patients with newly diagnosed multiple myeloma","volume":"78","author":"Kyle","year":"2003","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.clml.2016.06.006_bib25","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1126\/science.1164390","article-title":"Leukemic cells create bone marrow niches that disrupt the behavior of normal hematopoietic progenitor cells","volume":"322","author":"Colmone","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.clml.2016.06.006_bib26","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1182\/blood-2011-04-347484","article-title":"Multiple myeloma-related deregulation of bone marrow-derived CD34(+) hematopoietic stem and progenitor cells","volume":"120","author":"Bruns","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2016.06.006_bib27","doi-asserted-by":"crossref","first-page":"e148","DOI":"10.1038\/bcj.2013.34","article-title":"Long-term survival in multiple myeloma is associated with a distinct immunological profile, which includes proliferative cytotoxic T-cell clones and a favourable Treg\/Th17 balance","volume":"3","author":"Bryant","year":"2013","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2016.06.006_bib28","series-title":"Vaccines","year":"2008"},{"key":"10.1016\/j.clml.2016.06.006_bib29","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/ni.2039","article-title":"Immunological mechanisms of vaccination","volume":"12","author":"Pulendran","year":"2011","journal-title":"Nat Immunol"},{"key":"10.1016\/j.clml.2016.06.006_bib30","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1038\/leu.2012.189","article-title":"Suppression of uninvolved immunoglobulins defined by heavy\/light chain pair suppression is a risk factor for progression of MGUS","volume":"27","author":"Katzmann","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2016.06.006_bib31","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1086\/605664","article-title":"Infections in patients with multiple myeloma in the era of high-dose therapy and novel agents","volume":"49","author":"Nucci","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clml.2016.06.006_bib32","first-page":"1","article-title":"Immunization of the immunocompromised host","volume":"1","author":"Moss","year":"1998","journal-title":"Clin Focus Prim Immune Deficiencies"},{"issue":"suppl 1","key":"10.1016\/j.clml.2016.06.006_bib33","first-page":"9","article-title":"Advisory Committee on Immunization Practices (ACIP) recommended immunization schedule for adults aged 19 years and older\u2014United States, 2013","volume":"62","author":"Adult Immunization Work Group","year":"2013","journal-title":"MMWR Surveill Summ"},{"key":"10.1016\/j.clml.2016.06.006_bib34","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1097\/00001432-199508000-00006","article-title":"Immunization in the immunocompromised host","volume":"8","author":"Ljungman","year":"1995","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.clml.2016.06.006_bib35","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.autrev.2011.05.015","article-title":"Immunization in the adult immunocompromised host","volume":"11","author":"L\u00f6bermann","year":"2012","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.clml.2016.06.006_bib36","first-page":"678","article-title":"Immunosuppression and vaccine use","volume":"7","author":"Paulus","year":"2003","journal-title":"Clin J Oncol Nurs"},{"key":"10.1016\/j.clml.2016.06.006_bib37","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1503\/cmaj.080734","article-title":"Efficacy of pneumococcal vaccination in adults: a meta-analysis","volume":"180","author":"Huss","year":"2009","journal-title":"Can Med Assoc J"},{"key":"10.1016\/j.clml.2016.06.006_bib38","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/infdis\/jit442","article-title":"Aging promotes B-1b cell responses to native, but not protein-conjugated, pneumococcal polysaccharides: implications for vaccine protection in older adults","volume":"209","author":"Haas","year":"2014","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.clml.2016.06.006_bib39","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/0002-9343(80)90014-5","article-title":"Pneumococcal vaccination: the response of patients with multiple myeloma","volume":"69","author":"Lazarus","year":"1980","journal-title":"Am J Med"},{"key":"10.1016\/j.clml.2016.06.006_bib40","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/S0140-6736(94)90180-5","article-title":"Randomised trial of intravenous immunoglobulin as prophylaxis against infection in plateau-phase multiple myeloma. The UK Group for Immunoglobulin Replacement Therapy in Multiple Myeloma","volume":"343","author":"Chapel","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2016.06.006_bib41","first-page":"2238","article-title":"Compromised immune function in multiple myeloma","volume":"65","author":"Yoshida","year":"2007","journal-title":"Nihon Rinsho"},{"key":"10.1016\/j.clml.2016.06.006_bib42","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.trivac.2013.09.001","article-title":"Pneumococcal vaccine responses in elderly patients with multiple myeloma, Waldenstr\u00f6m's macroglobulinemia, and monoclonal gammopathy of undetermined significance","volume":"2","author":"Karlsson","year":"2013","journal-title":"Trials Vaccinol"},{"key":"10.1016\/j.clml.2016.06.006_bib43","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1128\/CVI.00654-15","article-title":"Poor correlation between pneumococcal IgG and IgM titers and opsonophagocytic activity in vaccinated patients with multiple myeloma and Waldenstr\u00f6m's macroglobulinemia","volume":"23","author":"Karlsson","year":"2016","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.clml.2016.06.006_bib44","unstructured":"Herper M. Pfizer vaccine study could change medicine (and boost stock). Forbes [Epub 2014 Feb 27]. Available at: http:\/\/www.forbes.com\/sites\/matthewherper\/2014\/02\/24\/pfizer-vaccine-study-could-change-medicine-boost-stock\/?partner=yahootix. Accessed February 22,\u00a02016."},{"key":"10.1016\/j.clml.2016.06.006_bib45","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1056\/NEJMoa1408544","article-title":"Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults","volume":"372","author":"Bonten","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2016.06.006_bib46","first-page":"822","article-title":"Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged\u00a0\u226565 years: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"63","author":"Tomczyk","year":"2014","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.clml.2016.06.006_bib47","first-page":"CD006505","article-title":"Vaccines for prophylaxis of viral infections in patients with hematological malignancies","author":"Cheuk","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.clml.2016.06.006_bib48","first-page":"1167","article-title":"Influenza vaccination in patients with cancer: an overview","volume":"24","author":"Boehmer","year":"2010","journal-title":"Oncology (Williston Park)"},{"key":"10.1016\/j.clml.2016.06.006_bib49","doi-asserted-by":"crossref","first-page":"3206","DOI":"10.1182\/blood.V122.21.3206.3206","article-title":"Boost vaccination improves humoral immune response against influenza virus in patients with multiple myeloma","volume":"122","author":"Hahn","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2016.06.006_bib50","doi-asserted-by":"crossref","first-page":"3","DOI":"10.5001\/omj.2013.02","article-title":"Multiple myeloma: an update","volume":"28","author":"Al-Farsi","year":"2013","journal-title":"Oman Med J"},{"key":"10.1016\/j.clml.2016.06.006_bib51","unstructured":"Centers for Disease Control and Prevention. Vaccination of hematopoietic stem cell transplant (HSCT) recipients (last updated Feb. 15, 2011). Available at: http:\/\/www.cdc.gov\/vaccines\/pubs\/hemato-cell-transplts.htm. Accessed May 10,\u00a02016."},{"key":"10.1016\/j.clml.2016.06.006_bib52","doi-asserted-by":"crossref","first-page":"4784","DOI":"10.1200\/JCO.2007.14.9641","article-title":"Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study","volume":"26","author":"Chanan-Khan","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2016.06.006_bib53","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/cncr.24006","article-title":"Acyclovir to prevent reactivation of varicella zoster virus (herpes zoster) in multiple myeloma patients receiving bortezomib therapy","volume":"115","author":"Vickrey","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2016.06.006_bib54","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1182\/blood-2009-10-163329","article-title":"How I treat elderly patients with myeloma","volume":"116","author":"Mehta","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2016.06.006_bib55","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1093\/jjco\/hyq194","article-title":"Low-dose acyclovir is effective for prevention of herpes zoster in myeloma patients treated with bortezomib: a report from the Korean Multiple Myeloma Working Party (KMMWP) retrospective study","volume":"41","author":"Kim","year":"2011","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.clml.2016.06.006_bib56","first-page":"1","article-title":"Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients","volume":"49","year":"2000","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.clml.2016.06.006_bib57","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.bbmt.2009.06.019","article-title":"Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective","volume":"15","author":"Tomblyn","year":"2009","journal-title":"Biol Blood Marrow Transpl"},{"key":"10.1016\/j.clml.2016.06.006_bib58","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1034\/j.1399-3062.1999.10105.x","article-title":"Preventing opportunistic infections in bone marrow transplant recipients","volume":"1","author":"Dykewicz","year":"1999","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.clml.2016.06.006_bib59","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1086\/321805","article-title":"Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients","volume":"33","author":"Dykewicz","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clml.2016.06.006_bib60","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1158\/1078-0432.CCR-11-1221","article-title":"Lenalidomide-induced immunomodulation in multiple myeloma: impact on vaccines and antitumor responses","volume":"18","author":"Noonan","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2016.06.006_bib61","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1111\/imm.12087","article-title":"Enhanced cross-priming of naive CD8+ T cells by dendritic cells treated by the IMiDs\u00ae immunomodulatory compounds lenalidomide and pomalidomide","volume":"139","author":"Henry","year":"2013","journal-title":"Immunology"},{"key":"10.1016\/j.clml.2016.06.006_bib62","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1136\/annrheumdis-2014-206016","article-title":"The proteasome inhibitor bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus","volume":"74","author":"Alexander","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clml.2016.06.006_bib63","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.6004\/jnccn.2015.0167","article-title":"Multiple Myeloma, version 2.2016: clinical practice guidelines in oncology","volume":"13","author":"Anderson","year":"2015","journal-title":"J\u00a0Natl Compr Canc Netw"},{"key":"10.1016\/j.clml.2016.06.006_bib64","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1093\/cid\/cit684","article-title":"2013 IDSA clinical practice guideline for vaccination of the immunocompromised host","volume":"58","author":"Rubin","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clml.2016.06.006_bib65","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1086\/598513","article-title":"Seasonal influenza in adults and children\u2014diagnosis, treatment, chemoprophylaxis, and institutional outbreak management: clinical practice guidelines of the Infectious Diseases Society of America","volume":"48","author":"Harper","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clml.2016.06.006_bib66","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.mayocp.2013.01.019","article-title":"Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013","volume":"88","author":"Mikhael","year":"2013","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.clml.2016.06.006_bib67","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1002\/ajh.24129","article-title":"Limiting early mortality: do's and don'ts in the management of patients with newly diagnosed multiple myeloma","volume":"91","author":"Gonsalves","year":"2016","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2016.06.006_bib68","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1385\/MO:19:2:71","article-title":"Cancer patients undergoing chemotherapy show adequate serological response to vaccinations against influenza virus and Streptococcus pneumoniae","volume":"19","author":"Nord\u00f8y","year":"2002","journal-title":"Med Oncol"},{"key":"10.1016\/j.clml.2016.06.006_bib69","doi-asserted-by":"crossref","first-page":"4131","DOI":"10.1182\/blood.V124.21.4131.4131","article-title":"Efficacy of the two-dose influenza vaccine in cancer patients receiving chemotherapy: a prospective study","volume":"124","author":"Sanada","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2016.06.006_bib70","doi-asserted-by":"crossref","first-page":"e2305","DOI":"10.1097\/MD.0000000000002305","article-title":"Risk of early mortality in patients with newly diagnosed multiple myeloma","volume":"94","author":"Hsu","year":"2015","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.clml.2016.06.006_bib71","doi-asserted-by":"crossref","first-page":"e285","DOI":"10.3324\/haematol.2014.116772","article-title":"Efficacy of single versus boost vaccination against influenza virus in patients with multiple myeloma","volume":"100","author":"Hahn","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2016.06.006_bib72","doi-asserted-by":"crossref","first-page":"3213","DOI":"10.1200\/JCO.2015.63.1275","article-title":"Key opinion leaders","volume":"33","author":"Steensma","year":"2015","journal-title":"J\u00a0Clin Oncol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265016301112?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265016301112?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:27:43Z","timestamp":1761870463000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265016301112"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9]]},"references-count":72,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["S2152265016301112"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2016.06.006","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2016,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vaccination in Multiple Myeloma: Review of Current Literature","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2016.06.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}